TNF inhibitor

Robert B Chao, MD doctorRBC
3 years 6 months ago
Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐️TNFi with slightly better drug retention
⭐️Age, BASDAI, BMI did not favor any group
⭐️inefficacy - main reason
#ACR21 @RheumNow https://t.co/ynoomYrTvX


swethaann23 swethaann23
3 years 6 months ago
⭐️Prevalent drug utilization was not related to enthesitis activity
⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i
⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx
Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P


Dr. John Cush RheumNow
3 years 6 months ago
Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting.
https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI


David Liew drdavidliew
3 years 6 months ago
Put those two RF together (essentially nailing down RA pts at risk of cancer):
age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30)
age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24)
neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55)
#ACR21 @RheumNow https://t.co/Uvr4wBhFVF

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?

Richard Conway RichardPAConway
3 years 6 months ago
Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disease control. Consistent across all rheumatic and non-rheumatic diseases. Abstr#1946 #ACR21 @RheumNow https://t.co/D1Ppb58fB8


Richard Conway RichardPAConway
3 years 6 months ago
ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq


David Liew drdavidliew
3 years 6 months ago
ORAL Surveillance: MACE and malignancy are getting all the attention...
but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis?
#ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j


Janet Pope Janetbirdope
3 years 6 months ago
Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. Note this outcome was not powered to be stat sig. it is a comparison of SIE events #ACR21 abst#1684 @RheumNow https://t.co/uqME6ABXuC


Dr. Rachel Tate uptoTate
3 years 6 months ago
Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or in nr-axSpA or AS. Failure of 1st TNFi didn't diminish effectiveness or drug survival of additional TNFi. Abs 0938 #ACR21 #RheumNow @RheumNow https://t.co/u1efnfv2zA https://t.co/qsJw3nA9qn


Olga Petryna DrPetryna
3 years 6 months ago
Abst1830 #ACR21 @RheumNow d/c of TNFi in PsA/PSO: probability of d/c TNFi ⬆️ by 9.6% for each additional biologic trial. Former smoker &PsA duration correlated w/ discontinuation. most commonly reason for d/c TNFi was secondary failure (33%). infliximab had lower d/c rate https://t.co/BXd2ALX2qo


Dr. Rachel Tate uptoTate
3 years 6 months ago
Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki
